BPA
ARKG icon

Beacon Pointe Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Beacon Pointe Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Sell
124,487
-1,995
-2% -$63.5K 0.02% 498
2026
Q1 		$3.34M Buy
126,482
+2,483
+2% +$72.7K 0.02% 591
2025
Q4 		$3.59M Sell
123,999
-2,437
-2% -$73.1K 0.03% 471
2025
Q3 		$3.51M Buy
126,436
+56,390
+81% +$1.42M 0.03% 429
2025
Q2 		$1.71M Buy
70,046
+1,607
+2% +$35.2K 0.02% 514
2025
Q1 		$1.42M Buy
+68,439
New +$1.72M 0.02% 546

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Beacon Pointe Advisors's ARKG Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its ARK Genomic Revolution ETF (ARKG) stake by 1.6% in Q2 2026, selling an estimated $63.5K and leaving 124,487 shares worth $5.24M. The position accounts for 0.02% of the portfolio, ranked #498.

Beacon Pointe Advisors first reported a position in ARKG in Q1 2025 and has held it in 6 quarters since. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Beacon Pointe Advisors held 124,487 shares of ARK Genomic Revolution ETF worth $5.24M as of Q2 2026.
  • Beacon Pointe Advisors sold 1,995 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $63.5K.
  • ARK Genomic Revolution ETF made up 0.02% of Beacon Pointe Advisors's portfolio in Q2 2026, its #498 holding.
  • Beacon Pointe Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2025 and has held it in 6 quarters since.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.